Use of the dual-antiplatelet therapy score to guide treatment duration after percutaneous coronary intervention

Annals of Internal Medicine

Volumn 167, Issue 1, 2017, Pages 17-25

  Piccolo, Raffaele ^a   Gargiulo, Giuseppe ^a   Franzone, Anna ^a   Santucci, Andrea ^a   Ariotti, Sara ^a   Baldo, Andrea ^a   Tumscitz, Carlo ^b   Moschovitis, Aris ^a   Windecker, Stephan ^a   Valgimigli, Marco ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY HOSPITAL OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

ACUTE HEART INFARCTION; ADULT; AGE; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL OUTCOME; CONGESTIVE HEART FAILURE; DEATH; DIABETES MELLITUS; DRUG ELUTING STENT; DUAL ANTIPLATELET THERAPY; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; HEART DEATH; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERTENSION; IN-STENT RESTENOSIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PACLITAXEL ELUTING STENT; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SEX DIFFERENCE; SMOKING; STENT THROMBOSIS; TREATMENT DURATION; VEIN GRAFT DISEASE; ANALOGS AND DERIVATIVES; BLEEDING; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; COMPLICATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG ADMINISTRATION; MIDDLE AGED; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIAL; STENT; TREATMENT OUTCOME;

AGED; ASPIRIN; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; RETROSPECTIVE STUDIES; STENTS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 85021845555     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M16-2389     Document Type: Article

References (23)

1. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, et al; Authors/Task Force members. 2014 ESC/EACTS guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35:2541-619. [PMID: 25173339] doi:10.1093/eurheartj/ehu278
2. Piccolo R, Giustino G, Mehran R, Windecker S. Stable coronary artery disease: revascularisation and invasive strategies. Lancet. 2015;386:702-13. [PMID: 26334162] doi:10.1016/S0140-6736 (15) 61220-X
3. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA guideline for the management of STelevation myocardial infarction, 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation. 2016;134:e123-55. [PMID: 27026020] doi: 10.1161/CIR.0000000000000404
4. Navarese EP, Andreotti F, Schulze V, Kolodziejczak M, Buffon A, Brouwer M, et al. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: metaanalysis of randomised controlled trials. BMJ. 2015;350:h1618. [PMID: 25883067] doi:10.1136/bmj.h1618
5. Valgimigli M, Ariotti S, Costa F. Duration of dual antiplatelet therapy after drug-eluting stent implantation: will we ever reach a consensus? [Editorial]. Eur Heart J. 2015;36:1219-22. [PMID: 25761893] doi:10.1093/eurheartj/ehv053
6. Spencer FA, Prasad M, Vandvik PO, Chetan D, Zhou Q, Guyatt G. Longer-versus shorter-duration dual-antiplatelet therapy after drugeluting stent placement: a systematic review and meta-analysis. Ann Intern Med. 2015;163:118-26. [PMID: 26005909] doi:10.7326/M15-0083
7. Bittl JA, Baber U, Bradley SM, Wijeysundera DN; Evidence Review Committee Members. Duration of dual antiplatelet therapy: a systematic review for the 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2016;134:e156-78. [PMID: 27026019] doi:10.1161/CIR.0000000000000405
8. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, et al; DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371:2155-66. [PMID: 25399658] doi:10.1056/NEJMoa1409312
9. Valgimigli M, Costa F, Byrne R, Haude M, Baumbach A, Windecker S. Dual antiplatelet therapy duration after coronary stenting in clinical practice: results of an EAPCI survey. EuroIntervention. 2015;11:68-74. [PMID: 25982650] doi:10.4244/EIJV11I1A11
10. Yeh RW, Secemsky EA, Kereiakes DJ, Normand SL, Gershlick AH, Cohen DJ, et al; DAPT Study Investigators. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA. 2016;315:1735-49. [PMID: 27022822] doi:10.1001/jama.2016.3775
11. Kereiakes DJ, Yeh RW, Massaro JM, Cutlip DE, Steg PG, Wiviott SD, et al; DAPT Study Investigators. DAPT score utility for risk prediction in patients with or without previous myocardial infarction. J Am Coll Cardiol. 2016;67:2492-502. [PMID: 27046159] doi:10.1016/j.jacc.2016.03.485
12. Valgimigli M, Campo G, Monti M, Vranckx P, Percoco G, Tumscitz C, et al; Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators. Short-versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation. 2012;125:2015-26. [PMID: 22438530] doi:10.1161/CIRCULATIONAHA.111.071589
13. Valgimigli M, Campo G, Percoco G, Monti M, Ferrari F, Tumscitz C, et al. Randomized comparison of 6-versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in allcomer patients undergoing percutaneous coronary intervention design and rationale for the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY). Am Heart J. 2010;160:804-11. [PMID: 21095265] doi:10.1016/j.ahj.2010.07.034
14. Valgimigli M, Borghesi M, Tebaldi M, Vranckx P, Parrinello G, Ferrari R; PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY Investigators. Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY). Eur Heart J. 2013;34:909-19. [PMID: 23315904] doi:10.1093/eurheartj/ehs460
15. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344-51. [PMID: 17470709]
16. Piccolo R, Eitel I, Galasso G, Dominguez-Rodriguez A, Iversen AZ, Abreu-Gonzalez P, et al. 1-year outcomes with intracoronary abciximab in diabetic patients undergoing primary percutaneous coronary intervention. J Am Coll Cardiol. 2016;68:727-38. [PMID: 27515333] doi:10.1016/j.jacc.2016.05.078
17. Parner ET, Andersen PK. Regression analysis of censored data using pseudo-observations. Stata J. 2010;10:408-22.
18. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ. 2003;326:219. [PMID: 12543843]
19. Généreux P, Giustino G, Witzenbichler B, Weisz G, Stuckey TD, Rinaldi MJ, et al. Incidence, predictors, and impact of post-discharge bleeding after percutaneous coronary intervention. J Am Coll Cardiol. 2015;66:1036-45. [PMID: 26314532] doi:10.1016/j.jacc.2015.06.1323
20. Vranckx P, White HD, Huang Z, Mahaffey KW, Armstrong PW, Van de Werf F, et al. Validation of BARC bleeding criteria in patients with acute coronary syndromes: the TRACER trial. J Am Coll Cardiol. 2016;67:2135-44. [PMID: 27151345] doi:10.1016/j.jacc.2016.02.056
21. Cassese S, Piccolo R, Galasso G, De Rosa R, Piscione F. Twelvemonth clinical outcomes of everolimus-eluting stent as compared to paclitaxel- and sirolimus-eluting stent in patients undergoing percutaneous coronary interventions. A meta-analysis of randomized clinical trials. Int J Cardiol. 2011;150:84-9. [PMID: 21315461] doi:10.1016/j.ijcard.2011.01.015
22. Kang SH, Chae IH, Park JJ, Lee HS, Kang DY, Hwang SS, et al. Stent thrombosis with drug-eluting stents and bioresorbable scaffolds: evidence from a network meta-analysis of 147 trials. JACC Cardiovasc Interv. 2016;9:1203-12. [PMID: 27262860] doi:10.1016/j.jcin. 2016.03.038
23. Windecker S, Stortecky S, Stefanini GG, da Costa BR, Rutjes AW, et al. Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. BMJ. 2014;348:g3859. [PMID: 24958153] doi:10.1136/bmj.g3859